|  | Cancer | Lymphoma

Prognosis for Mantle Cell Lymphoma

Mantle cell lymphoma is a type of cancer that appears in the outer layer of the lymph nodes. Although new treatment advances have improved the success rate of this rare form of lymphoma, the long-term prognosis for the disease is still not good, according to the Leukemia and Lymphoma Society.

  1. Identification

    • Mantle cell lymphoma is generally considered low grade, meaning that it progresses slowly; however, the cancer often spreads to the spleen, liver or bone marrow. In such cases, your chances of successfully recovering from the cancer decrease, according to LymphomaInfo.net.

    Time Frame

    • The average survival rate of mantle cell lymphoma is four years, reports the the Leukemia and Lymphoma Society.

    Features

    • Mantle cell lymphoma typically responds well to the initial treatment used for the cancer, and patients usually experience an average of a 20-month period of remission following this initial treatment. Unfortunately, as reported by the Leukemia and Lymphoma Society, the disease usually returns and becomes more difficult to treat.

    Types of Treatment

    • Treatments for mantle cell lymphoma include chemotherapy, stem cell transplants, radioimmunotherapy and protease-inhibiting drugs. Often doctors rely upon consolidated therapy or on using one type of treatment right after another.

    Considerations

    • The survival rates for mantle cell lymphoma are simply averages. Your individual prognosis depends upon a number of factors, including your general health, your age and the progression of your cancer.

Lymphoma - Related Articles